Although WEE1, PLK1, and AURKA kinase inhibitors have been studied in HNSCC and other cancers, small molecule inhibitors targeting other G2/M kinases such as TTK are currently in preclinical or clinical development (36, 37). Here, PLK1 is linked to cancer.